| Identification |
| Name: | Mubritinib |
| Synonyms: | 1-(4-[4-[(2-[(E)-2-[4-(Trifluoromethyl)phenyl]ethenyl]-1,3-oxazol-4-yl)methoxy]phenyl]butyl)-1H-1,2,3-triazole; |
| CAS: | 366017-09-6 |
| Molecular Formula: | C25H23F3N4O2 |
| Molecular Weight: | 468.47 |
| InChI: | InChI=1/C25H23F3N4O2/c26-25(27,28)21-9-4-20(5-10-21)8-13-24-30-22(18-34-24)17-33-23-11-6-19(7-12-23)3-1-2-15-32-16-14-29-31-32/h4-14,16,18H,1-3,15,17H2/b13-8+ |
| Molecular Structure: |
![(C25H23F3N4O2) 1-(4-[4-[(2-[(E)-2-[4-(Trifluoromethyl)phenyl]ethenyl]-1,3-oxazol-4-yl)methoxy]phenyl]butyl)-1H-1,2,...](https://img1.guidechem.com/chem/e/dict/34/366017-09-6.jpg) |
| Properties |
| Density: | 1.25g/cm3 |
| Refractive index: | 1.577 |
| Biological Activity: | Potent, irreversible human epithelial growth factor receptor 2 (ErbB2) inhibitor (IC 50 = 6 nM) that displays > 4000-fold selectivity over EGFR, FGFR, PDGFR, JAK1 and Src. Exhibits potent antiproliferative effects in ErbB2-overexpressing cancer cell lines (IC 50 = 5 nM in BT474 breast cancer cells) and significantly inhibits bladder, breast and prostate cancer xenograft growth in vivo . |
| Safety Data |
| |
 |
